TROGLITAZONE ON SUBSTRATE METABOLISM AND BODY COMPOSITION IN DIABETES

$0M01FY2000RRNIH

Washington University, Saint Louis MO

Investigators

Linked publications & trials

Paper 39587896 Paper 38712131 Paper 38278947 Paper 37292813 Paper 37186949 Paper 35643360 Paper 34320286 Paper 34029510 Paper 33479058 Paper 33071178 Paper 33002231 Paper 32064729 Paper 31886931 Paper 31685489 Paper 31505070 Paper 31418516 Paper 31404238 Paper 31303390 Paper 31167889 Paper 31118516 Paper 31028280 Paper 30967435 Paper 30455329 Paper 30421439 Paper 29936086 Paper 29758564 Paper 29697830 Paper 29427697 Paper 29415895 Paper 29398050 Paper 29246363 Paper 29157731 Paper 28983117 Paper 28664624 Paper 28378429 Paper 27803118 Paper 27677166 Paper 27557777 Paper 27533307 Paper 27367781 Paper 27173125 Paper 27161901 Paper 27057209 Paper 27048307 Paper 26856247 Paper 26798573 Paper 26628417 Paper 26577415 Paper 26574956 Paper 26537182 Paper 26531295 Paper 26443692 Paper 26336641 Paper 26322147 Paper 26173465 Paper 26106190 Paper 25888511 Paper 25784663 Paper 25783161 Paper 25702853 Paper 25690268 Paper 25500725 Paper 25227934 Paper 25115882 Paper 25018070 Paper 24948348 Paper 24835502 Paper 24819707 Paper 24698320 Paper 24529412 Paper 24450390 Paper 24418810 Paper 24388323 Paper 24334183 Paper 24156898 Paper 24139497 Paper 24136113 Paper 24119040 Paper 24095133 Paper 24084071 Paper 24054930 Paper 24043256 Paper 23993815 Paper 23908125 Paper 23836730 Paper 23704677 Paper 23704675 Paper 23704674 Paper 23704673 Paper 23704672 Paper 23601134 Paper 23552360 Paper 23498594 Paper 23438494 Paper 23409789 Paper 23400602 Paper 23287844 Paper 22938716 Paper 22923682 Paper 22891254

Abstract

Type II diabetes mellitus (DM) is characterized by hepatic and peripheral insulin resistance. Troglitazone and Metformin are two insulin-sensitizing agents that reduce hepatic glucose production and improve glucose control. The effects of these agents on whole-body glucose production, adipose tissue lipolytic rates, insulin sensitivity, and body composition will be assessed in 24 individuals with insulin-requiring type II DM who undergo 12 weeks of Troglitazone or Metformin therapy.

View original record on NIH RePORTER →